hVIVO is a contract research organisation best known for running human challenge studies, in which carefully screened volunteers are deliberately exposed to a characterised pathogen under controlled conditions. These studies allow vaccine and antiviral developers to gather early evidence of efficacy faster, and often …
ImmuPharma develops novel medicines, with its research rooted in peptide science. Its best-known programme is P140, previously branded Lupuzor, a candidate therapy for systemic lupus erythematosus, a chronic autoimmune condition in which the immune system attacks the body's own tissues. The approach behind P140 …
Inspiration Healthcare designs, manufactures and supplies medical technology, with a particular focus on neonatal intensive care. Its products are used by hospitals to support premature and critically ill infants, and include neonatal ventilation systems, along with other equipment and consumables used in neonatal units. …
Diaceutics works at the intersection of diagnostics and pharmaceuticals. Precision medicines, such as many targeted cancer therapies, depend on patients being identified through diagnostic testing before treatment. If testing is slow, inconsistent or unavailable, patients may miss out on suitable therapies and drug launches …
ECO Animal Health develops and sells animal health products, primarily for the poultry and pig sectors, through a global network spanning China, North America, Latin America, South East Asia and other markets. Its established business has been built around antibiotic and pharmaceutical products for …
Bioventix, based in Farnham, Surrey, specialises in the development and commercial supply of high-affinity monoclonal antibodies, with a particular focus on sheep monoclonal antibodies, often referred to as SMAs. These antibodies are used as key components in in vitro diagnostic tests, the blood tests …
The reported 11.11% rise is consistent with recovery interest following the latest annual trading update. That update indicated higher revenue, accelerating commercial momentum and progress with the German launch of Grassmuno.
The reported +6.23% rise is consistent with the latest update showing higher sales, improved gross profit and positive earnings before interest, tax, depreciation and amortisation. The company also described an expanding customer base.
The reported +5.56% rise is consistent with renewed attention to bexmarilimab and the latest announcement that final melanoma-cohort results would be presented at a forthcoming oncology meeting. This improves scientific visibility.
ProBiotix Health (LSE:PBX) is attracting attention because of its latest corporate or operating update.